Exploring Electroporation Series Part 1: Immunotherapy
MaxCyte is at the forefront of developing cancer immunotherapies through cutting-edge genome engineering and sophisticated strategies. The company's electroporation technology is pivotal in the new era in the engineering of NK and T cells, delivering a variety of payloads into primary cells that are usually challenging to transfect. This technique ensures cell viability and facilitates the production of accurately engineered cells in large quantities, paving the way for swift and clinically scalable manufacturing processes. This collection of articles discusses techniques such as CRISPR electroporation of T cells, multiplexed NK cell engineering, and the use of transposons for efficient CAR T cell engineering. Discover how we are inching closer to the realization of potent and personalized immunotherapies.
If you enjoy this Cell Therapy E-book, check out the remainder of the series:
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.